MSH2 and colorectal carcinoma: Although risk group-specific performance of FIT could not be assessed in our study, individuals having variants in the higher-risk genes MLH1 or MSH2 (11) could potentially be tested with FIT halfway through the 2-yearly colonoscopy interval, aiming to reduce the postcolonoscopy CRC rate.